1. Apollo Hospitals Enterprise: 

Prabhudas Lilladher maintains its ‘Buy’ rating on this healthcare facilities company, with a target price of Rs 9,350, an upside of 13.2%. Apollo Hospitals reported healthy Q4FY26 results, with revenue rising 17.6% YoY, thanks to better occupancy rates, improvements across business segments, and capacity expansion. Net profit climbed 35.9% due to better pricing and increased demand for the higher-margin complex procedures.

Analysts Param Desai and Sanketa Kohale view the stake sale in HealthCo (diagnostics arm) to Advent and the merger with pharma distributor, Keimed, as positive steps toward building an integrated pharmacy and digital health platform. They expect profitability to improve as the company scales Apollo HealthCo and brings its digital business to EBITDA breakeven in the coming quarters. Management plans a capex of Rs 1,980 crore in FY27 to add approximately 1,000 beds.

Desai and Kohale noted that the demerger of its omnichannel pharmacy business, 24*7, and telehealth business into a newly listed entity, Apollo Healthtech, will unlock value, creating a high-growth platform. Analysts project a revenue CAGR of 15.8% and an EBITDA CAGR of 25% over FY27–28.

2. Astral: 

IDBI Capital upgrades this building materials manufacturer to a ‘Buy’ call, with a target price of Rs 1,714 per share, an upside of 8.6%. Analysts Archana Gude and Parth Mandavgane turned positive on Astral after the company reported a strong Q4FY26 recovery and guided for healthy growth across its core businesses. Revenue rose 24.2% YoY, while net profit grew 19.6%, helped by the expanding paints business.

Management noted that polymer prices, the main raw material for plastic pipes, have likely stopped falling after a three-year decline. Prices may rise again from July 1 due to higher import duties. This shift could squeeze unorganised competitors who struggle with price volatility, allowing organised players like Astral to gain market share. Astral anticipates its plumbing pipe volumes to grow 10–15% in FY27, with overall piping revenue rising 20–25%.

Gude and Mandavgane highlight Astral's efforts to boost profitability through its new in-house CPVC resin project, scheduled to start production by Q4FY27. Producing this key raw material internally should reduce manufacturing costs and expand margins. Management expects the project to improve piping margins by 200 basis points.

3. Anthem Biosciences: 

BOB Capital Markets retains its ‘Buy’ rating on this pharma company, with an upgraded target price of Rs 900, a 16.5% upside. Anthem delivered strong Q4FY26 results, with revenue climbing 33.1% YoY due to rising contract development and manufacturing (CDMO) volumes. Net profit surged 129.7%, helped by lower raw material costs and a higher-margin product mix.

Analyst Foram Parekh believes Anthem's expertise in high-barrier biological molecules and its robust client relationships will drive future earnings. Management targets long-term revenue growth of 20% and EBITDA margins of 38–43%. To support this, the company plans to spend Rs 200 crore on a new manufacturing facility to double its custom synthesis capacity and expand fermentation capacity by 50% by FY28.

Management expects its generic-side GLP-1 (diabetes & weight-loss drug) active pharmaceutical ingredient (API) sales to begin over the next 6-8 months. The company is also undergoing discussions with major Indian GLP-1 players to supply these APIs to replace imports from China. Parekh estimates EBITDA margins to expand further as Anthem increases capacity utilisation, scales up commercial sales, and begins manufacturing key raw materials in-house. She projects a revenue CAGR of 20% and a net profit CAGR of 28% through FY29.

4. Gland Pharma: 

ICICI Direct maintains its ‘Buy’ call on this pharma company, with a target price of Rs 2,645, an upside of 14.6%. The company posted a strong Q4FY26 performance, with revenue growing 22% YoY. A 24% increase in the US and a 36% jump in Europe drove this performance. Together, these two markets contribute nearly 79% of the company’s total revenue.

Management expects annual revenue to grow by around 15% over the next four years, with a larger increase in FY29 as it launches more complex and high-value medicines. To support this, Gland Pharma plans to invest Rs 2,000 crore over the next five years to expand capacity in ophthalmic drugs, specialty injectables, sterile manufacturing, and contract development and manufacturing (CDMO) services. However, Middle East shipping disruptions delayed some Q4 shipments, particularly to Saudi Arabia.

Analysts Siddhant Khandekar and Shubh Mehta project revenue and net profit to grow at CAGRs of 15% and 25%, respectively, over FY27–28. They believe the expanding CDMO business, improving operations at its European unit Cenexi, and future opportunities in weight-loss and diabetes (GLP-1) drugs will support long-term growth.

5. Karnataka Bank: 

Anand Rathi maintains its ‘Buy’ call on this public bank, with a target price of Rs 330, an upside of 23.3%. Karnataka Bank delivered mixed Q4FY26 results as revenue dipped 0.9% YoY due to weaker treasury income, while net profit jumped 61.6%. Analysts Yuvraj Choudhary and Sagar Rungta remain positive, citing improved lending yields, lower funding costs, and better asset quality as key earnings drivers.

Management estimates margins to remain stable as they shift the loan portfolio toward higher-yielding products. They forecast credit growth of 15–20% in FY27, driven by retail, agricultural, and micro, small and medium enterprises (MSME) loans. Analysts believe the bank’s net interest margin will remain steady at around 3.1%, as increased earnings from loans help offset rising funding costs.

Choudhary and Rungta note that the bank plans to phase out its lower-yielding inter-bank participation certificates and redeploy that capital into higher-yielding MSME loans. Analysts project an 11.6% CAGR for net interest income and a 5% CAGR for net profit over FY27–28.

Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

(You can find all analyst picks here)